Bruesewitz v. Wyeth LLC, 562 U.S. 223 (2011) (U.S. Supreme Court)
Bruesewitz v. Wyeth is a cornerstone case at the intersection of products liability, federal preemption, and public health policy.
Does the National Childhood Vaccine Injury Act of 1986, 42 U.S.C. § 300aa-22(b)(1), preempt all state-law design-defect claims against vaccine manufacturers for vaccine-related injuries where the vaccine was properly manufactured and accompanied by proper directions and warnings?
Under the NCVIA, a vaccine manufacturer is not liable in a civil action for damages arising from a vaccine-related injury or death if the injury or death resulted from side effects that were unavoidable even though the vaccine was properly prepared and accompanied by proper directions and warnings. 42 U.S.C. § 300aa-22(b)(1). The Act establishes a comprehensive no-fault compensation program (the VICP), requires claimants to proceed first through that program, and preserves only certain traditional tort claims (notably, manufacturing defect and certain failure-to-warn claims) while preempting design-defect claims.
Yes. The NCVIA preempts all state-law design-defect claims against vaccine manufacturers for vaccine-related injuries when the vaccine was properly prepared and accompanied by proper directions and warnings. The judgment for Wyeth was affirmed.
Bruesewitz is a leading case on statutory preemption in products liability and a blueprint for analyzing Congress's redesign of remedies in heavily regulated industries. For practitioners, it definitively forecloses state-law design-defect suits against vaccine manufacturers for covered vaccines, channeling claims to the Vaccine Court and to the limited tort avenues the NCVIA preserves. For students, it is a model of textualist reasoning grounded in statutory structure and purpose, and it highlights the interplay among federal regulation, tort law, and public health policy. The case also provides a useful contrast with decisions like Wyeth v. Levine, underscoring that preemption outcomes turn on statutory text and regulatory frameworks, not on a general pro- or anti-preemption posture.